The alternative CD20 transcript variant is not a surrogate marker for resistance to rituximab in patients with rheumatoid arthritis.

Clémentine Gamonet Marina Deschamps Sandrine Marion Georges Herbein Gilles Chiocchia Isabelle Auger Philippe Saas Christophe Ferrand Eric Toussirot

Rheumatology (Oxford)

Université de Franche Comté, UPRES EA 4266 Agents Pathogènes et Inflammation, Besançon, INSERM, CIC 1431, Centre investigation Clinique Biothérapie, Fédération Hospitalo-Universitaire INCREASE, CHRU, CHRU Besançon, Rhumatologie and Université de Franche Comté, Département Universitaire de Thérapeutique, Besançon, France

Published: September 2015

Download full-text PDF	Source
http://dx.doi.org/10.1093/rheumatology/kev210	DOI Listing

Publication Analysis

Top Keywords

alternative cd20

cd20 transcript

transcript variant

variant surrogate

surrogate marker

marker resistance

resistance rituximab

rituximab patients

patients rheumatoid

rheumatoid arthritis

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!